CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $5.8M, lower than 95% of all stocks globally
- PositionDebt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.30MGBP5.80M · vs all stocks (USD)
Revenue (TTM)
0.00GBPvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.37xvs all stocks
52-Week Change
-11.11%vs all stocks
Market Capitalization
4.30MGBP5.80M · vs all stocks (USD)
Enterprise Value
801.93KGBP1.08M · vs all stocks (USD)
Forward P/E
-1.74xvs Biotechnology peers
Price to Book (MRQ)
1.05xvs Biotechnology peers
Enterprise to EBITDA
-0.3630xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-28.77%vs Biotechnology peers
Return on Equity (TTM)
-53.79%vs Biotechnology peers
Revenue (TTM)
0.00GBPvs all stocks (USD)
Revenue per Share (TTM)
0.00GBPUpdated Aug 9, 2026Gross Profit (TTM)
-2.23MGBP-3.02M · vs all stocks (USD)
EBITDA (TTM)
-2.21MGBP-2.98M · vs all stocks (USD)
Net Income (TTM)
-2.01MGBP-2.71M · vs all stocks (USD)
Operating Cash Flow (TTM)
-1.70MGBP-2.29M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
352.88KGBP476.57K · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00GBPUpdated Aug 9, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00GBPFY2025 · Mar 31, 2025Operating Income
-2.12MGBP-2.86M · vs all stocks (USD)
Pre-tax Income
-2.08MGBPFY2025 · Mar 31, 2025Income Tax Expense
-144.00KGBPFY2025 · Mar 31, 2025Net Income
-1.94MGBPFY2025 · Mar 31, 2025EBIT
-2.12MGBPFY2025 · Mar 31, 2025EBITDA (Income Statement)
-2.05MGBPFY2025 · Mar 31, 2025Research & Development
1.08MGBPFY2025 · Mar 31, 2025Selling, General & Administrative
904.00KGBPFY2025 · Mar 31, 2025Non-operating Interest Income
5.00KGBPFY2025 · Mar 31, 2025EPS (Basic)
-0.0036GBPFY2025 · Mar 31, 2025EPS (Diluted)
-0.0036GBPFY2025 · Mar 31, 2025Basic Shares Outstanding
538.31MSharesFY2025 · Mar 31, 2025Diluted Shares Outstanding
538.31MSharesFY2025 · Mar 31, 2025Preferred Stock Dividends
0.00GBPFY2025 · Mar 31, 2025Operating Cash Flow
-1.89MGBPFY2025 · Mar 31, 2025Cash & Cash Equivalents (End of Period)
2.11MGBPFY2025 · Mar 31, 2025Starting Profit (CF Statement)
-2.08MGBPFY2025 · Mar 31, 2025Stock-based Compensation
117.00KGBPFY2025 · Mar 31, 2025Other Non-cash Items
-5.00KGBPFY2025 · Mar 31, 2025Change in Accounts Receivable (CF)
82.00KGBPFY2025 · Mar 31, 2025Net Acquisitions
-75.00KGBPFY2025 · Mar 31, 2025Net Investing Cash Flow
-75.00KGBPFY2025 · Mar 31, 2025Net Financing Cash Flow
5.15MGBPFY2025 · Mar 31, 2025Shares Outstanding
2.15BSharesUpdated Aug 9, 2026Float Shares
1.23BSharesUpdated Aug 9, 2026% Held by Insiders
45.65%vs all stocks
% Held by Institutions
16.79%vs all stocks
Total Cash (MRQ)
3.50MGBP4.72M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.0020GBPUpdated Aug 9, 2026Total Debt (MRQ)
0.00GBPvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Biotechnology peers
Current Ratio (MRQ)
2.29xvs Biotechnology peers
Book Value per Share (MRQ)
0.0020GBPUpdated Aug 9, 2026Total Assets
7.63MGBP10.30M · vs all stocks (USD)
Total Current Assets
5.17MGBPFY2025 · Mar 31, 2025Total Liabilities
1.66MGBPFY2025 · Mar 31, 2025Total Non-current Assets
2.46MGBPFY2025 · Mar 31, 2025Total Non-current Liabilities
-1.00KGBPFY2025 · Mar 31, 2025Total Current Liabilities
1.66MGBPFY2025 · Mar 31, 2025Cash
2.11MGBPFY2025 · Mar 31, 2025Cash & Cash Equivalents
2.11MGBPFY2025 · Mar 31, 2025Other Short-term Investments
2.00MGBPFY2025 · Mar 31, 2025Accounts Receivable
387.00KGBPFY2025 · Mar 31, 2025Accounts Payable
106.00KGBPFY2025 · Mar 31, 2025Common Stock (Book)
5.32MGBPFY2025 · Mar 31, 2025Retained Earnings
-30.43MGBPFY2025 · Mar 31, 2025Total Shareholders' Equity
5.97MGBP8.06M · vs all stocks (USD)
52-Week Low
0.1750GBXUpdated Aug 9, 202652-Week High
0.3000GBXUpdated Aug 9, 202652-Week Change
-11.11%vs all stocks
Beta
1.37xvs all stocks
50-Day MA
0.2192GBXUpdated Aug 9, 2026200-Day MA
0.2129GBXUpdated Aug 9, 2026Avg 10-Day Volume
2.28MSharesUpdated Aug 9, 2026Avg 30-Day Volume
2.15MSharesUpdated Aug 9, 2026Diluted EPS (TTM)
-0.0036GBPUpdated Aug 9, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)Notable
Debt-to-equity: 0.00Industry median: 0.09Industry P5: 0.00Peers compared: 261
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 2.29Altman Z-Score: -4.39
Financial Health
Altman Z-Score -4.39: distress zoneCritical
Altman Z-Score: -4.39
Low earnings qualitySignificant
Earnings Quality Score: -0.86
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $5.8M, lower than 95% of all stocks globallySignificant
Market cap (USD): 5,804,479.986Global P5: 269,387,740.27
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Purple Biotech Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
XTL Biopharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sulzer Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Thalia Therapeutics Plc
Tier 1ProductionApproval-Gated PipelineRule
Nuformix Plc
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Sailong Pharmaceutical Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Crism Therapeutics Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Futura Medical plc
Tier 1ProductionApproval-Gated PipelineRule
Cizzle Biotechnology Holdings Plc
Tier 1ProductionApproval-Gated PipelineRule
Genflow Biosciences Plc
Tier 1ProductionApproval-Gated PipelineRuleRisk